Can AI Crack the Code on Fibrosis?

Animate Biosciences launches AnimateIQ, with early data showing reduced inflammation and fibrosis markers in lab and animal studies

27 Feb 2026

Artificial intelligence has long promised to shorten the slow march from laboratory insight to medicine. Animate Biosciences, a young biotech firm, now claims to be edging that promise closer to practice. It has launched AnimateIQ, an AI-driven platform designed to speed the discovery of peptide drugs for inflammatory and fibrotic diseases.

Peptides, short chains of amino acids, can bind to biological targets with precision. That makes them appealing in disorders marked by chronic inflammation and tissue scarring, from lung and liver disease to heart and skin conditions. Yet identifying the right peptide has often relied on laborious testing. AnimateIQ seeks to replace much of that trial and error with algorithms that design and refine candidates in silico before they reach the bench.

In newly released preclinical studies, several AI-designed peptides reduced markers of inflammation and fibrosis in human cell systems and in animals. The results are early and remain confined to the laboratory. Still, they suggest that computational models can translate complex biological data into plausible molecular designs. Whether such candidates will prove safe and effective in humans is another matter; many promising compounds fail in clinical trials.

The firm argues that generating and filtering molecules digitally should cut costs and lower failure rates. By prioritising the most promising candidates sooner, it hopes to compress the time between discovery and viable drug. That ambition is widely shared. Across the pharmaceutical industry, AI tools are becoming embedded in research strategies. Companies such as 1910 are also advancing machine-guided peptide design, reflecting a broader turn towards data-driven discovery.

Yet fibrosis is stubbornly complex. Scar-forming pathways vary across tissues and patients, complicating translation from model systems to clinics. Regulators, too, are still refining how to assess compounds whose origins lie partly in code.

If platforms like AnimateIQ can repeatedly deliver candidates that survive clinical testing, early stage drug discovery may look very different. For now, AI remains a powerful tool, one whose true value will be measured not in models, but in medicines.